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Abstract
Purpose—The primary treatment modality for patients with carcinoma of the esophagus or 
gastroesophageal junction has been surgery, although primary radiation therapy with concurrent 
chemotherapy produces similar results. As both have curative potential, there has been great 
interest in the use of trimodality therapy. To this end, we compared survival, response, and patterns 
of failure of trimodality therapy to esophagectomy alone in patients with nonmetastatic esophageal 
cancer.
Patients and Methods—Four hundred seventy-five eligible patients were planned for 
enrollment. Patients were randomly assigned to either esophagectomy with node dissection alone 
or cisplatin 100 mg/m2 and fluorouracil 1,000 mg/m2/d for 4 days on weeks 1 and 5 concurrent 
with radiation therapy (50.4 Gy total: 1.8 Gy/fraction over 5.6 weeks) followed by esophagectomy 
with node dissection.
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Results—Fifty-six patients were enrolled between October 1997 and March 2000, when the trial 
was closed due to poor accrual. Thirty patients were randomly assigned to trimodality therapy and 
26 were assigned to surgery alone. Patient and tumor characteristics were similar between groups. 
Treatment was generally well tolerated. Median follow-up was 6 years. An intent-to-treat analysis 
showed a median survival of 4.48 v 1.79 years in favor of trimodality therapy (exact stratified log-
rank, P = .002). Five-year survival was 39% (95% CI, 21% to 57%) v 16% (95% CI, 5% to 33%) 
in favor of trimodality therapy.
Conclusion—The results from this trial reflect a long-term survival advantage with the use of 
chemoradiotherapy followed by surgery in the treatment of esophageal cancer, and support 
trimodality therapy as a standard of care for patients with this disease.
INTRODUCTION
Surgery has been the mainstay of treatment for patients with esophageal cancer. Radiation 
therapy with concurrent chemotherapy without resection results in survival outcomes that 
are similar to surgery, although local recurrence rates are approximately 50%. Five-year 
survival rates remain approximately 20% with either strategy. Adjuvant chemotherapy has 
not been proven to be beneficial in this disease, although there may be a differential response 
between adenocarcinoma and squamous cell cancers. The use of both neoadjuvant and 
adjuvant chemotherapy, at times coupled with radiation, have shown benefit in selected 
individual trials in patients with gastric and gastroesophageal junction cancers.1,2
There has been substantial interest in whether the use of all three modalities would be 
superior to surgery alone. A number of single-institution trials have been performed.3–5 The 
most commonly used agents have been fluorouracil (FU) and cisplatin. Drugs such as 
taxanes and oxaliplatin have not demonstrated superiority to FU and cisplatin. Thus, the GI 
Intergroup, led by the Cancer and Leukemia Group B (CALGB), initiated a trial testing 
surgery alone versus trimodality therapy with radiation therapy, FU, and cisplatin in patients 
with nonmetastatic esophageal squamous or adenocarcinomas.
PATIENTS AND METHODS
Eligibility
Patients with histologically documented untreated squamous cell carcinoma or 
adenocarcinoma of the thoracic esophagus (below 20 cm) or gastroesophageal junction and 
with less than 2 cm distal spread into the gastric cardia were eligible. There could be no 
evidence of distant metastatic disease by history and physical examination; upper endoscopy 
with biopsy, computed tomography (CT) of the chest and upper abdomen, and pulmonary 
function studies were all required. Bone scan was required for alkaline phosphatase more 
than 3× the institutional normal value. Bronchoscopy was required if the primary tumor was 
adjacent to the trachea or left main stem bronchus. Patients were required to have 
granulocyte counts ≥ 1,800/mL, platelet count ≥100,000/mL, and a creatinine clearance ≥ 50 
mL/min. Esophageal ultrasound (EUS) and preresection staging by thoracoscopy (ts) and 
laparoscopy/minilaparotomy (ls), including biopsy of celiac axis and lesser curvature, were 
recommended.
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Tumors had to be considered surgically resectable (T1-3, NX), including regional thoracic 
lymph node (N1) metastases. Patients with supraclavicular lymph nodes measuring ≤ 1.5 cm 
by CT (not palpable) were eligible, as were patients with lymph node metastases to levels 15 
to 20 (predominantly celiac axis and paracardial nodes) ≤ 1.5 cm by CT. Patients could not 
have previously received chemotherapy or radiation therapy for this tumor or any radiation 
therapy that would overlap the radiation fields required for this malignancy. Patients with 
previous malignancies were eligible if more than 5 years had elapsed from diagnosis without 
evidence of tumor recurrence.
There could be no other serious illness that would limit survival to less than 2 years, or 
psychiatric condition that would prevent compliance with treatment or informed consent. 
Patients with uncontrolled or severe cardiovascular disease, pulmonary disease, or active 
infections were excluded, as were pregnant patients. The protocol was approved by 
institutional review boards at all study sites, and informed consent was required for all 
patients.
Treatment Plan
Patients were randomly assigned to treatment with preoperative chemoradiotherapy followed 
by surgery or surgery alone. Random assignment was stratified by thoracic nodal status as 
determined by CT (N0; N+), prestudy staging (invasive or noninvasive), and cancer type 
(squamous or adenocarcinoma). Trimodality therapy began within 21 days of random 
assignment. Chemotherapy and radiotherapy were to begin within 24 hours of each other.
Radiotherapy (1.8 Gy/5 d/wk) was begun within 24 hours of the administration of 
chemotherapy, and continued for 5.5 weeks (50.4 Gy). The final 5.4 Gy treatment was given 
as a boost. Radiation fields extended 5 cm beyond the proximal and distal extent of tumor, 
and the lateral borders extended 2 cm beyond the apparent mass. Supraclavicular lymph 
nodes were included if the tumor extended 2 cm above the carina. If the primary tumor was 
in the distal third of the esophagus or if the celiac nodes were radiographically enlarged (but 
< 1.5 cm), the radiation fields were enlarged to include this target. The cone-down fields 
included the primary tumor with a 2-cm margin. Dosage was prescribed at the isocenter.
Cisplatin 100 mg/m2 bolus intravenous infusion was given during 30 minutes on days 1 and 
29 with standard prehydration and antiemetic therapy. FU 1,000 mg/m2/day was 
administered as a continuous intravenous infusion for 96 hours after completion of the 
cisplatin on days 1 through 4 and 29 through 32.
Within 4 weeks after radiation therapy, patients were restaged with a chest and abdomen CT 
and repeat esophagogastroduodenoscopy. Patients with progressive or unresectable disease 
were removed from protocol therapy and observed for survival.
Surgery was optimally performed 3 to 8 weeks after completion of chemoradiotherapy, and 
within 6 weeks of randomization for patients randomly assigned to surgery alone. Resection 
via left chest or right chest and abdomen (Ivor-Lewis) was recommended for 
midesophageal- and gastroesophageal-junction cancers. Transhiatal esophagectomy was 
discouraged. All technically accessible lymph nodes were to be removed. The mediastinal or 
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deep surgical margin was marked by the surgeon and pathologist. A microscopic lateral or 
deep margin of less than 1 mm was considered a positive margin, and proximal and distal 
margins of at least 2 cm beyond gross tumor was desired.
Definition of Response
A complete pathologic response was defined as no gross or microscopic tumor in the 
surgical specimen using light microscopy, but not immunohistochemical stains (primary and 
nodes). A partial pathologic response was defined as shrinkage in tumor size compared with 
the original esophagogastroduodenoscopy. This was subclassified as macroscopic (evident at 
time of surgery) or microscopic (evident only at pathology review) residual disease. An 
increase in ≥ 25% of the product of perpendicular diameters at the indicator lesion, or the 
appearance of new lesions, was defined as progressive disease. Stable disease was defined as 
not qualifying as a partial or complete pathologic response or progressive disease.
Resections were defined as curative (R0) when all gross disease was removed with negative 
margins. Incomplete resection (R1) was defined as residual gross disease or positive surgical 
margins (tumor ≤ 1 mm from any margin).
Statistical Methods
The primary objective of this study was to determine whether trimodality therapy improves 
overall survival (OS) when compared to surgery alone. Secondary end points included 
response, local and distant control rates, and progression-free survival (PFS).
A target sample of 475 eligible patients was to be randomly assigned with equal probability 
to each treatment arm. The targeted sample size was inflated to 500 patients to account for 
ineligibility. Patients were grouped as previously described.
With 475 eligible patients enrolled onto the study for more than 5 years and observed for an 
additional 3 years, 90% power is achieved to detect a survival hazard ratio of 1.4 (two-sided 
α = .05) corresponding under exponential survival to a difference between 20% and 32% in 
5-year OS. Formal interim analyses of OS were planned when 50%, 75%, and 100% of the 
expected number of events (n = 371) were observed.6 Surgical mortality was to be 
monitored when 100, 200, 300, and 400 patients had been enrolled. Accrual would be 
curtailed if the mortality rate was 20% or greater on the trimodality treatment arm.
The exact χ2 test was used to compare patient characteristics between treatment arms for 
categoric variables and the Van der Waerden (normal) score test was used to compare patient 
characteristics measured as continuous variables. OS was calculated as the time from study 
entry to death or date last known alive (censored). PFS was calculated from date of study 
entry to documented tumor progression or recurrence, death, or date last known to be 
progression free (censored). These time-to-event distributions were estimated using the 
method of Kaplan-Meier,7 and compared using two-sided exact stratified log-rank tests.8 
Equality of the censoring distributions between treatment arms was assumed. The analyses 
were performed using an intent-to-treat approach, including all patients as randomly 
assigned regardless of eligibility or treatment. The Cox proportional hazards model9 was 
used to estimate the 95% CI for the OS and PFS hazard ratios, controlling for the 
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stratification factors. Median follow-up was estimated among surviving patients. The 
recurrence site was defined as local (gastric or esophageal bed, or regional lymph nodes) or 
distant (supraclavicular lymph node, liver, peritoneal carcinomatosis, lung, or brain).
Patient registration, random assignment, and data collection were managed by the CALGB 
Statistical Center and monitored by the CALGB data safety monitoring board. In particular, 
central randomization was conducted by telephone via the CALGB Statistical Center 
Registrar, who independently confirmed eligibility but was not involved in any other aspect 
of the trial’s conduct. Toxicity was graded according to the CALGB Expanded Common 
Toxicity Criteria. Analyses were based on the study database frozen on January 18, 2006, 
and were performed using SAS (Statistical Analysis System, Cary, NC) software. Analyses 
of OS and PFS were also conducted using StatXact, version 8 (Cytel Software Corp Inc, 
Cambridge, MA). A P value less than .05 was considered significant (Fig 1).
RESULTS
Patient and Tumor Characteristics
A total of 56 patients were enrolled onto the study between October 1997 and March 2000. 
Despite efforts to boost enrollment, the accrual rate to the trial remained low and the trial 
was closed. Thirty patients were randomly assigned to trimodality therapy and 26 were 
randomly assigned to surgery alone. Forty-three percent of patients were enrolled by 16 
CALGB Institutions, 34% by the North Central Cancer Treatment Group, and 21% by 
Radiation Therapy Oncology Group.
Patient and tumor characteristics were similar between groups (Tables 1 and 2). Fifty-two 
patients (93%) met study eligibility criteria. Four patients failed to meet eligibility criteria, 
one due to T4 disease, the second due to gastric spread, the third because of two primaries, 
and the fourth due to lack of prestudy pulmonary function studies. Ineligible patients were 
included in all analyses per intent-to-treat.
Staging
Fourteen of 26 patients assigned to surgery alone were staged by EUS, and six of 26 were 
staged by ts/ls. Fifteen of 30 patients assigned to trimodality therapy were staged by EUS, 
and eight of 30 were staged by ts/ls. Patients were evaluated for stage using all staging tests 
available for each patient.
Toxicity
Data on grade 3 or greater toxicity were reported on 28 patients treated with preoperative 
therapy, and on 18 patients treated with surgery alone. Fifty-seven percent of patients 
receiving preoperative therapy experienced at least one occurrence of hematologic toxicity 
of grade 3 or greater. Nonhematologic toxicity included esophagitis/dysphagia (42%), 
infection (34%), and pain (24%). There was one treatment-related death due to infection 
(4%). Table 3 lists all grade 3 or greater toxicities reported as adverse events in at least 10% 
of patients treated with trimodality therapy.
Tepper et al. Page 5














Data on surgical procedures were available for 52 patients, 26 of 30 of whom were receiving 
trimodality therapy and all 26 patients on the surgery-alone arm. No surgical data are 
available for four patients on the trimodality arm; one died from treatment-related infection 
before surgery, and three patients refused surgery. Of the 52 patients for whom data on 
surgical procedure were available, seven underwent exploration surgery only, one underwent 
left thoracotomy or thoracoabdominal surgery, 30 underwent Ivor-Lewis surgery, eight 
underwent celiotomy/right thoracotomy/cervical surgery, and six underwent transhiatal 
surgery. Of the seven patients who underwent exploratory surgery only, four were randomly 
assigned to trimodality therapy and three were assigned to surgery alone. Of the four 
patients assigned to trimodality therapy, two patients had metastases. No reason was 
provided for the exploratory-only surgery for the other two patients. Of the three patients 
randomly assigned to surgery alone, two had metastases and one had T4 disease.
Surgical complications were reported for 48 of the 52 patients reporting a surgical procedure 
(24 in each treatment arm). These complications were reported as related to surgery (Table 
4), and were not reported as adverse events in Table 3. Median postoperative hospital stay 
was 11.5 days (range, 3 to 56 days) and 10.0 days (range, 3 to 24 days) for the trimodality 
and surgery-alone arms, respectively. One patient on the surgery-alone arm died within 30 
days of surgery from surgical complications.
Response
Pathologic response data were available for 25 patients treated with preoperative 
chemoradiotherapy. The best pathologic response to neoadjuvant treatment was complete 
response (10 patients), partial response (microscopic; two patients), partial response 
(macroscopic; eight patients), stable disease (two patients), and progression (two patients). 
One patient was not assessable. Three of the six patients with N1 disease pretreatment were 
downstaged to N0 with preoperative therapy.
Survival
Median follow-up was 6 years (5.8 years after surgery alone and 6.1 years after trimodality 
therapy) with 57.5 and 109.9 person-years followed for the surgery alone and trimodality 
treatment arms, respectively. Median OS was 4.48 (95% CI, 2.4 years to not estimable) v 
1.79 years (95% CI, 1.41 to 2.59 years) in favor of trimodality therapy (Fig 2). The 95% CI 
estimate of the OS hazard ratio is 1.46 to 5.69. Five-year OS was 39% (95% CI, 21% to 
57%) v 16% (95% CI, 5% to 33%) for trimodality therapy versus surgery alone.
Median PFS was 3.47 years (95% CI, 1.31 to 4.76 years) among patients treated with 
preoperative chemoradiotherapy versus 1.01 years (95% CI, 0.22 to 1.46 years) among 
patients treated with surgery alone (Fig 3). The 95% CI estimate of the PFS hazard ratio is 
1.37 to 5.32. Five-year PFS was 28% (95% CI, 12% to 47%) and 15% (95% CI, 4% to 33%) 
for trimodality therapy versus surgery alone. No interim analyses were performed on these 
end points.
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Sites of recurrence were reported for nine patients on the trimodality arm and 12 on the 
surgery alone arm. On the trimodality arm, three patients had both local and distant 
recurrences, five had distant recurrence only, and one had local recurrence only. On the 
surgery arm, one patient had both local and distant recurrence, nine had distant recurrence 
only, and three had local recurrence only.
Of the 20 patients for whom data on site of recurrence were not available, nine died without 
documented failure, nine came off treatment for reasons other than recurrence or death, and 
two had no reported site of failure.
DISCUSSION
For many years, the most commonly used therapy for esophageal cancer was surgical 
resection alone. Radiation Therapy Oncology Group trial 8501, which compared 6,400 cGy 
radiation therapy alone versus 5,000 cGy with concurrent FU and cisplatin, showed 5-year 
survival rates of 32% v 12% in favor of combined-modality therapy.10,11 Although survival 
was adequate with radiochemotherapy, local control was poor, with local failure in almost 
50% of patients.
There has been great interest in the use of adjuvant chemotherapy. The GI Intergroup trial 
0113 did not demonstrate an advantage to pre- and postoperative chemotherapy with FU and 
cisplatin compared with surgery alone. In contrast, the Medical Research Council study, 
using the same drugs given preoperatively, demonstrated a 3.5-month improvement in 
median survival.12
Despite the fact that surgery is more commonly used, there has been limited information to 
suggest that either surgery or radiation/chemotherapy is a superior approach. Stahl et al13 
randomly assigned patients with squamous cell carcinomas to either induction chemotherapy 
followed by radiochemotherapy and surgery, or the same induction chemotherapy followed 
by high-dose radiochemotherapy without surgery. There was no statistical difference in 
survival, but local progression-free rates were superior in the surgery cohort. Given that both 
surgical and nonsurgical approaches are good therapies, this raises the question about 
whether combining both would be superior to either modality alone.
A number of studies have been run to test the efficacy of preoperative radiochemotherapy 
compared with surgery alone14–18; FU and cisplatin were the most common drugs 
employed. The results have been mixed, and have not resolved the issue of whether there is a 
survival advantage to trimodality therapy. A recent trial from Australia18 did not 
demonstrate an advantage to trimodality therapy compared with surgery alone overall, 
although there was a benefit for the patients with squamous cell carcinoma.
There have been a number of meta-analyses of randomized trials of surgery versus surgery 
and radiochemotherapy,19–22 and these have generally shown an advantage to trimodality 
therapy. The most recent meta-analysis, performed by Gebski et al,23 includes 10 studies and 
demonstrates a hazard ratio for mortality of 0.81 in favor of trimodality therapy.
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The present study was designed to gather more information on this topic, enrolling 475 
eligible patients during 5 years. Despite repeated efforts, the study investigators were unable 
to overcome physician biases, patient preferences, and the consequent inability to randomly 
assign more patients. The poor accrual led to early closure, with only 56 patients enrolled.
The results indicate a benefit in OS and PFS with trimodality therapy. There was no 
suggestion that operative mortality was increased by the use of trimodality therapy, and the 
preoperative treatment was accomplished with manageable toxicity. Although not planned, 
this resulted in being a trial primarily of adenocarcinoma, with only one fourth of the 
patients having squamous cell carcinomas.
A major limitation of this trial is the small sample size. To address this issue, CIs on median 
OS and PFS by treatment arm and on the OS and PFS hazard ratios were provided, and an 
exact permutation test was used to compare the survival end points between treatment arms. 
Results based on the asymptotic distributions were corroborated by the results using the 
exact test. The validity of the exact test relies on the assumption of equal censoring 
distributions between arms. Despite the curtailed study period, this assumption should be 
reasonable given the prospective randomized design and planned patient treatment, and 
follow-up. Although the accrual period was curtailed, the projected length of the follow-up 
period was realized. Follow-up data on PFS and OS were obtained by direct contact with 
participating institutions. Loss to follow-up was low (5%), with only two patients receiving 
trimodality therapy (at 0.27 and 2.6 years, respectively), and one patient receiving surgery 
alone (at 1.15 years) observed less than 3 years.
We acknowledge that there exists a publication bias for a trial of this sort in that positive 
trials would be published and negative trials might be ignored. Regardless, the results of this 
study have value in that they arise from a well-designed, cooperative-group clinical trial, and 
provide further evidence regarding the efficacy of trimodality therapy in this setting.
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Kaplan-Meier estimates of overall survival (OS) by treatment arm measured from study 
entry until death from any cause. (*) NE, not estimable. †Asymptotic results for OS were 
comparable to those obtained using the exact method.
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Kaplan-Meier estimates of progression-free survival (PFS) by treatment arm measured from 
study entry until documented progression of disease or death from any cause. (*) NE, not 
estimable. †Asymptotic results for PFS were comparable to those obtained using the exact 
method.
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Table 2
No. of Patients Per Treatment Arm by T and N Stage
Stage No. of Patients
T N Trimodality Therapy Surgery Alone
2 0 2 1
2 1 1 1
3 0 17 20
3 1 9 3
4 0 1 0
Unknown 0 0 1
Total 30 26
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Table 4
Reported Surgical Complications (No. of occurrences) by Treatment Arm for Patients Undergoing Surgical 
Procedures (n = 48)
Surgical Complication Trimodal Therapy (n = 24) Surgery (n = 24)
Red blood count transfusion 9 4
Postoperative fever 6 8
Wound infection 3 3
Empyema 2 2
Bronchial fistula 0 1
Air leak 1 1
Atelectasis 0 2
Pneumonia with antibiotics 5 3
Respiratory failure 2 4
Splenectomy 1 0
Anastomotic strict/leak 2 0




Weight loss 5 6
Dysphagia 2 1
Tacheo-esophageal fistula 2 0
Dysrhythmia 1 2
Myocardial infarction 0 1
Deep vein thrombosis 1 0
Pulmonary embolism 1 0
Other 5 4
Postoperative death 0 1
Total postoperative, days
 Median 11.5 10.0
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Surgical Complication Trimodal Therapy (n = 24) Surgery (n = 24)
 Range 3–56 3–24
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